Nov 22,2021

Effects of Alternate Insulin Pump Settings in Patients With Type 1 Diabetes During Ramadan: A Randomized Pilot Study

Various studies have evaluated the safety and efficacy of using insulin pumps during Ramadan; some of them demonstrated favorable outcomes in reducing hypoglycemia and hyperglycemia. However, there is no consensus on the recommendations for basal insulin adjustments and the utilization of technical features of insulin pumps to improve glycemic control.

CLINICAL STUDY

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 23,2021

Start of the first human clinical trials for K’Watch Glucose

PKvitality, a French company specializing in health and sports "bio-wearables", announces the start of a clinical study to determine the accuracy of K'Watch Glucose . This study is being conducted with the AMCR Institute, a clinical research center specializing in diabetes and obesity with world-renowned expertise in metabolic medical devices.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 07,2021

Nemaura Medical Completes Initial Shipment of CGM Devices to UK Licensee

emaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that it has completed its initial shipment of sugarBEAT® continuous glucose monitor (CGM) devices to its UK licensee, MySugarWatch Limited (“MySugarWatch”), previously DB Ethitronix Limited.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 10,2021

Needle Technology for Insulin Administration: A Century of Innovation

Innovations in syringe and pen needle (PN) technology over the last 100 years have led to important advances in insulin delivery for people with diabetes, paralleling the strides made in developing recombinant DNA human insulin and insulin analogs with varying onset and duration of action. In this review, the history of advances in insulin delivery is described, focusing on progress in syringe, needle, and PN technologies.These developments, coupled with innovations in needle/PN wall and tip structure, have led to improved injection experience for people with diabetes. It is also important to acknowledge the role of injection technique education, together with these advances in injection technology, for improving clinical outcomes and patient satisfaction. With continued projected growth of diabetes prevalence, particularly in developing countries where expensive and complex insulin delivery systems may not be practical, insulin syringes and pens will continue to serve as reliable and cost-effective means of insulin delivery for people with diabetes.

CLINICAL STUDY

#insulin pen

#insulin pump

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 15,2021

Reliability of Inpatient CGM: Comparison to Standard of Care

Optimal inpatient glycemic management targets a blood glucose (BG) of 140-180 mg/dL and is an important safety measure for hospitalized patients with hyperglycemia. Traditional barriers to appropriate insulin administration include incorrect timing of prandial insulin administration, failure to administer basal insulin to persons with insulin deficiency/type 1 diabetes mellitus (DM), and inaccurate insulin dosing or timing resulting in hypoglycemia. Given the ongoing rapid assimilation of technology to manage our patients with DM, we investigated the use of continuous glucose monitoring (CGM) in the inpatient setting as a potential solution to traditional barriers to optimal hyperglycemia management for inpatient care. In this study, we evaluated the efficacy of use of inpatient CGM for insulin dosing in comparison with current standard of care and whether CGM could aid in minimizing hypoglycemic events.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 21,2021

Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System. The Eversense NOW iOS platform has previously been approved and is currently available in Europe.

REGULATORY CE MARK

#cgm

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 21,2021

Indigo Diabetes Business Update

Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of medical solutions using nanophotonics, today provides an update on recent and ongoing business activities.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 22,2021

CMS expands diabetes Medicare coverage to include CGMs that integrate with Medtronic insulin pumps

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of continuous glucose monitors (CGMs), including adjunctive and non-adjunctive CGMs. This includes CGMs that integrate with Medtronic insulin pumps. The proposed rule was finalized on December 21, 2021 and will be effective starting 60 days after official publication.

PRODUCT

#cgm

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jan 01,2020

Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease

The data suggest that CGM metrics may provide clinicians and researchers especially valuable information for evaluating risk of diabetes complications

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jan 08,2020

Microfabrication of bioimpedance sensors

Utilizing carbon nanotube technology, Tula in partnership with Brigham Young University has been able to miniaturize bioimpedence sensors.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM